Immunotherapies for hepatocellular carcinoma
The DOI matches its Crossref record; 216 of the 217 references it cites were found in a registry or an index.
Abstract
Liver cancer, more specifically hepatocellular carcinoma (HCC), is the second leading cause of cancer-related death and its incidence is increasing globally. Around 50% of patients with HCC receive systemic therapies, traditionally sorafenib or lenvatinib in the first line and regorafenib, cabozantinib or ramucirumab in the second line. In the past 5 years, immune-checkpoint inhibitors have revolutionized the management of HCC. The combination of atezolizumab and bevacizumab has been shown to improve overall survival relative to sorafenib, resulting in FDA approval of this regimen. More recently, durvalumab plus tremelimumab yielded superior overall survival versus sorafenib and atezolizumab plus cabozantinib yielded superior progression-free survival. In addition, pembrolizumab monotherapy and the combination of nivolumab plus ipilimumab have received FDA Accelerated Approval in the second-line setting based on early efficacy data. Despite these major advances, the molecular underpinnings governing immune responses and evasion remain unclear. The immune microenvironment has crucial roles in the development and progression of HCC and distinct aetiology-dependent immune features have been defined. Inflamed and non-inflamed classes of HCC and genomic signatures have been associated with response to immune-checkpoint inhibitors, yet no validated biomarker is available to guide clinical decision-making. This Review provides information on the immune microenvironments underlying t…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Over the past two decades, the development of effective systemic therapies has substantially improved the outcomes of patients with advanced-stage HCC2–6.”
From Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma (2024) · cites this paper as [5]
In the citing paper
“In the liver, the immune microenvironment primarily comprises immunosuppressive cells and signals that create a tolerogenic niche1,5,59.”
From Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma (2024) · cites this paper as [5]
In the citing paper
“Key cells involved in immune evasion in HCC include tissue-resident macrophages (Kupffer cells), regulatory T (Treg) cells, monocyte-derived macrophages and immature granulocytic cells often collectively referred to as myeloid-derived suppressor cells (MDSCs)5 (Fig. 1).”
From Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma (2024) · cites this paper as [5]
In the citing paper
“Currently, the main immunotherapeutic approach for patients with HCC — regardless of tumour stage — involves restoring antitumour immunity with ICIs, which are monoclonal antibodies that block inhibitory checkpoints or their ligands5.”
From Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma (2024) · cites this paper as [5]
In the citing paper
“For patients with advanced-stage HCC, the current availability of ~10 systemic regimens1,2,5,35,40 has resulted in a shift from median OS durations of 6–8 months to 19–20 months after first-line treatment and 10–14 months after second-line treatment (Fig. 4a).”
From Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma (2024) · cites this paper as [5]
Citations
Cites
Items 201–216 of 216
Energy metabolism and cell motility defect in NK-cells from patients with hepatocellular carcinoma
Zecca, A., Barili, V., Canetti, D., Regina, V., Olivani, A., Carone, C., Capizzuto, V., Zerbato, B., Trenti, T., Valle, R. D., et al. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02561-4 · Cited by 31
Craig, A. J., García‐Lezana, T., de Galarreta, M. R., Villacorta-Martín, C., Gonzalez‐Kozlova, E., Martins-Filho, S. N., von Felden, J., Ahsen, M. E., Bresnahan, E. R., Hernandez‐Meza, G., et al. (2021) · PLoS Genetics · doi:10.1371/journal.pgen.1009589 · Cited by 31
Self-citationDucreux, M. P., Abou‐Alfa, G. K., Ren, Z., Edeline, J., Li, Z., Assénat, E., Rimassa, L., Blanc, J. F., Ross, P. J., Fang, W. J., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.05.005 · Cited by 31
Gao, M., Huang, A., Sun, Z., Sun, Y. H., Chang, B., Zhang, J., & Zou, Z. (2018) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.14109 · Cited by 28
Rimola, J., da Fonseca, L. G., Sapena, V., Perelló, C., Guerrero, A. F., Torner, M., Pons, M., de la Torre‐Aláez, M., Márquez, L., Calleja, J. L., et al. (2020) · European Journal of Radiology · doi:10.1016/j.ejrad.2020.109484 · Cited by 28
Pinato, D. J., Cole, T., Bengsch, B., Tait, P., Sayed, A. A., Abomeli, F., Gramenitskaya, D., Allara, E., Thomas, R., Ward, C. E., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz247.076 · Cited by 27
Self-citationZhuang, P., Shen, J., Zhu, X., Lu, L., Wang, L., Tang, Z., & Sun, H. (2013) · PLoS ONE · doi:10.1371/journal.pone.0064598 · Cited by 26
Hazards in the plating industry.
Le, J. (1966) · PubMed · Cited by 19
Hepatitis C virus modulates signal peptide peptidase to alter host protein processing
Hirano, J., Yoshio, S., Sakai, Y., Li, S., Suzuki, T., Itoh, Y., Zhang, H., Chen, D. V., Haga, S., Oomori, H., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2026184118 · Cited by 19
Halperin, D. M., Johnson, M. L., Chan, J. A., Hart, L. L., Cook, N., Patel, V. M., Schlechter, B. L., Cave, J., Dowlati, A., Blaszkowsky, L. S., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.2021.39.15_suppl.4110 · Cited by 19
Goyal, L., Frigault, M. J., Meyer, T., Feun, L. G., Bruix, J., El-Khoueiry, A. B., Hausner, P. F., Sangro, B., Pierce, T. T., Norry, E., et al. (2019) · Cancer Research · doi:10.1158/1538-7445.am2019-3183 · Cited by 13
Self-citationPikarsky, E., & Heikenwälder, M. F. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.09.029 · Cited by 11
Self-citationYen, C.-J., Markman, B., Chao, Y., Hill, A., Kang, J., Wang, L., Li, K., Qi, Q., Wu, Z., & Gan, H. K. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx261.139 · Cited by 11
Bomze, D., Azoulay, D., & Meirson, T. (2020) · JAMA Oncology · doi:10.1001/jamaoncol.2020.0628 · Cited by 9
Esteban-Fabró, R., Willoughby, C. E., Piqué‐Gili, M., Peix, J., Montironi, C., Abril‐Fornaguera, J., Torrens, L., Pinyol, R., & Llovet, J. M. (2020) · Journal of Hepatology · doi:10.1016/s0168-8278(20)30632-2 · Cited by 7
Self-citationMarron, T. U., Gunasekaran, G., Tabrizian, P., Kim, E., Fiel, M. I., Ward, S. C., Zhao, Z., Doroshow, D. B., Legg, M., Hammad, A., et al. (2021) · Cancer Research · doi:10.1158/1538-7445.am2021-ct182 · Cited by 4
Research works printed but not linked: 2
- Tabrizian, P. et al. A US multicenter analysis of 2529 HCC patients undergoing liver transplantation: 10‐year outcome assessing the role of down‐staging to within Milan criteria. Hepatology 70, 10A–11A (2019).
- AstraZeneca. Imfinzi plus tremelimumab significantly improved overall survival in HIMALAYA Phase III trial in 1st-line unresectable liver cancer. astrazeneca.com, https://www.astrazeneca.com/media-centre/press-releases/2021/imfinzi-and-tremelimumab-improved-os-in-liver-cancer.html (15 October 2021).
Cited by
Singal, A. G., Kanwal, F., & Llovet, J. M. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00825-3 · Cited by 951
“ICIs have since revolutionized the management of advanced-stage HCC 233 .”
BackgroundSelf-citationEvolving therapeutic landscape of advanced hepatocellular carcinoma
Yang, C., Zhang, H., Zhang, L., Zhu, A. X., Bernards, R., Qin, W., & Wang, C. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-022-00704-9 · Cited by 727
Self-citationMolecular pathogenesis and systemic therapies for hepatocellular carcinoma
Llovet, J. M., Pinyol, R., Kelley, R. K., El-Khoueiry, A., Reeves, H. L., Wang, X. W., Gores, G. J., & Villanueva, A. (2022) · Nature Cancer · doi:10.1038/s43018-022-00357-2 · Cited by 498
Self-citationBiology and therapeutic targeting of vascular endothelial growth factor A
Pérez-Gutiérrez, L., & Ferrara, N. (2023) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-023-00631-w · Cited by 484
“Nevertheless, bevacizumab and other anti-VEGF agents have proven their utility in multiple cancer types and, over the last few years, in combination with immune-checkpoint inhibitors, have advanced the treatment of difficult-to-treat malignancies 257–259 .”
BackgroundLlovet, J. M., Kudo, M., Merle, P., Meyer, T., Qin, S., Ikeda, M., Xu, R., Edeline, J., Ryoo, B.-Y., Ren, Z., et al. (2023) · The Lancet Oncology · doi:10.1016/s1470-2045(23)00469-2 · Cited by 469
Self-citation
Metadata
- Authors
- Llovet, J. M., Castet, F., Heikenwalder, M., Maini, M. K., Mazzaferro, V., Pinato, D. J., Pikarsky, E., Zhu, A. X., & Finn, R. S.
- Affiliations
- Institució Catalana de Recerca i Estudis Avançats (ES)
- Hospital Clínic de Barcelona (ES)
- University College London (GB)
- University of Milan (IT)
- Università degli Studi del Piemonte Orientale “Amedeo Avogadro” (IT)
- Hebrew University of Jerusalem (IL)
- Massachusetts General Hospital (US)
- University of California, Los Angeles (US)
- Corresponding author
- Llovet, Josep M.
- ORCID
- Venue
- Nature Reviews Clinical Oncology
- Published
- 2021-11-11
- Volume
- 19
- Issue
- 3
- Pages
- 151-172
- ISSN
- 1759-4774 (ISSN-L)
- 1759-4782
- OpenAlex
- W3212903603
- Cited by
- 1,843
- References
- 217
- Citations by year
- 2026: 306 · 2025: 406 · 2024: 498 · 2023: 428 · 2022: 204
- FWCI
- 37.67
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature Reviews Clinical Oncology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Wellcome Trust (214191/Z/18/Z, PS3416)
- Cancer Research UK (26603, 26813, C57701/A26137)
- National Institute of Diabetes and Digestive and Kidney Diseases (R01DK056621, R01DK128289)
- Topics
- Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Keywords
- hepatocellular carcinoma, immune checkpoint inhibitors, tumor immune microenvironment, atezolizumab, bevacizumab, durvalumab, tremelimumab, pembrolizumab, nivolumab, ipilimumab, immune evasion, immune-related adverse events, immunotherapy resistance, first-line and second-line therapy, liver cancer
- MeSH terms
- Sorafenib, Immune Checkpoint Inhibitors, Carcinoma, Hepatocellular, Humans, Immunotherapy, Liver Neoplasms, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.